Cargando…

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions

The role of cytochrome P450 (CYP)2C9 and CYP2C19 genetic variation in risk for phenytoin‐induced cutaneous adverse drug events is not well understood independently of the human leukocyte antigen B (HLA‐B)*15:02 risk allele. In the multi‐ethnic resource for Genetic Epidemiology Research on Adult Heal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fohner, Alison E., Rettie, Allan E., Thai, Khanh K., Ranatunga, Dilrini K., Lawson, Brian L., Liu, Vincent X., Schaefer, Catherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485959/ https://www.ncbi.nlm.nih.gov/pubmed/32216088 http://dx.doi.org/10.1111/cts.12787

Ejemplares similares

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
por: Silvado, Carlos Eduardo, et al.
Publicado: (2018)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
por: Guevara, Natalia, et al.
Publicado: (2017)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)‐Warfarin
por: Wanounou, Maor, et al.
Publicado: (2022)

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
por: Pierre-François, Marie Josette Déborah, et al.
Publicado: (2022)

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
por: Sandhu, Amrit K., et al.
Publicado: (2023)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
por: Stingl, Julia Carolin, et al.
Publicado: (2022)

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
por: Lee, Su-Jun
Publicado: (2013)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity
por: Nissen, Mette S., et al.
Publicado: (2018)

Comparison of CYP2C9 Activity in Ethiopian and Non-Ethiopian Jews Using Phenytoin as a Probe
por: Abu Ghosh, Zahi, et al.
Publicado: (2020)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes
por: Tron, Camille, et al.
Publicado: (2022)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
por: Nizamuddin, Sheikh, et al.
Publicado: (2021)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy
por: Jose, Manna, et al.
Publicado: (2014)

Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
por: John, Shobana, et al.
Publicado: (2021)

Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy
por: Chaudhary, Nagendra, et al.
Publicado: (2016)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
por: Fohner, Alison E., et al.
Publicado: (2021)

Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
por: Larsen, Jens Borggaard, et al.
Publicado: (2017)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content
por: Shirasaka, Y, et al.
Publicado: (2016)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
por: Cacabelos, Ramón, et al.
Publicado: (2012)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

How genetic variation was analyzed in phenytoin-induced gingival enlargement using single-nucleotide polymorphism of candidate gene CYP2C9?
por: Balakrishnan, Premalatha, et al.
Publicado: (2020)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Functional characterization of the defective CYP2C9 variant CYP2C9*18
por: Liu, Jian, et al.
Publicado: (2021)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug
por: George, Melvin, et al.
Publicado: (2012)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c1nlj22f9h1kmppcotc8nm9r1j